Lumos Diagnostics Holdings (ASX:LDX) 6-Month Price Index: 0.36 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lumos Diagnostics Holdings 6-Month Price Index?

Lumos Diagnostics Holdings ASX:LDX 6-Month Price Index is 0.36 as of Aug. 28, 2026. The stock has 6 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-28), Lumos Diagnostics Holdings's 6-Month Price Index is 0.36.

Lumos Diagnostics Holdings  (ASX:LDX) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Lumos Diagnostics Holdings 6-Month Price Index Related Terms

ASX:LDX vs ABT, SYK, MDT: 6-Month Price Index Comparison

For the Medical Devices subindustry, Lumos Diagnostics Holdings's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings  (ASX:LDX) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.36 mean?
Lumos Diagnostics Holdings (ASX:LDX) has a 6-Month Price Index of 0.36 as of Aug. 28, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' 6-Month Price Index too high?
Lumos Diagnostics Holdings' current 6-Month Price Index is 0.36.
How does Lumos Diagnostics Holdings' 6-Month Price Index compare to ABT and SYK?
Lumos Diagnostics Holdings' 6-Month Price Index of 0.36 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current 6-Month Price Index is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.10 — trading 233.3% above its estimated fair value. The current 6-Month Price Index is 0.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current 6-Month Price Index is 0.36 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.